iBET’s Strong Contribution to Bioprocessing Summit Europe 2025
Researchers Delivered 2 Keynotes, 1 Featured & 3 Oral Presentations
From March 18-20, several iBET researchers participated in the 8th Annual Bioprocessing Summit Europe 2025 (Barcelona, Spain), gathering professionals from academia and industry to discuss innovations in the development, manufacturing, and quality control of antibodies, vaccines, and gene therapies.
iBET participated in the conference with two keynotes and one featured presentation:
-Prof. Paula Alves (CEO of iBET) delivered a keynote on “Leveraging Cell and Gene Therapy Products’ Quality Through a Bioanalytics Avenue” highlighting iBET’s recent work in highresolution, high-sensitivity advanced analytics for ATMPs and their critical role in regulatory compliance and potency assay development.
-Ana Sofia Coroadinha (Head of Cell Line Development and Molecular Virology Lab) delivered a keynote on “Extending AAV Genome Cargo for the Delivery of Large Therapeutic Genes: Treating Duchenne Muscular Dystrophies”. The talk addressed the challenge of delivering large therapeutic genes using AAV vectors and how mini-dystrophin proteins could be reconstituted with a Dual-AAV vector co-delivery system developed at iBET.
-Cristina Peixoto (Head of Downstream Process Development Lab and co-coordinator of Late Stage R&D and Bioproduction Unit) spoke about “Streamlining the Purification of a Clinical- Grade Oncolytic Virus for Therapeutic Applications”, outlining the development of an end-to-end process for a novel chimeric oncolytic virus, and the use of advanced analytics to ensure product quality and consistency.
Additionally, iBET scientist also presented three other oral presentations:
-Inês Isidro (Head of Biosystems and Data Science Team) – “Accelerating Design of New Upstream
Bioprocesses with Digital Twins: A Case Study on AAV Production”.
-Sofia Fernandes – “Optimising rAAV Production: The Role of Adenoviral Helper Components and AAV Promoter Activity”.
-Ricardo Correia – “An Improved CRISPR-Cas9 Protein-based Method for Knocking Out Insect Sf9 Cell Genes”.
iBET’s strong presence at the summit underscores its leadership in bioprocessing innovation and
its commitment to advancing next-generation biologics and genetic therapies.
